-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
-
Summary
-
Acrivon Therapeutics, Inc. quarterly/annual General and Administrative Expense history and change rate from 2022 to Q3 2025.
- Acrivon Therapeutics, Inc. General and Administrative Expense for the quarter ending September 30, 2025 was $6.04M, a 3.78% decline year-over-year.
- Acrivon Therapeutics, Inc. General and Administrative Expense for the twelve months ending September 30, 2025 was $25.1M, a 2.54% increase year-over-year.
- Acrivon Therapeutics, Inc. annual General and Administrative Expense for 2024 was $25.2M, a 19.6% increase from 2023.
- Acrivon Therapeutics, Inc. annual General and Administrative Expense for 2023 was $21.1M, a 142% increase from 2022.
General and Administrative Expense, Trailing 12 Months (USD)
General and Administrative Expense, Quarterly (USD)
General and Administrative Expense, YoY Quarterly Change (%)
General and Administrative Expense, Annual (USD)
General and Administrative Expense, YoY Annual Change (%)